Crohn's Disease Clinical Trials in Philadelphia

Showing 101-120 of 131 trials

Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics

NCT02316678

The investigators will test the hypothesis that that greater efficacy of anti-tumor necrosis factor (antiTNF) therapy results in reduced need for bowel resection surgery, fewer serious infections, and reduced short term mortality risks, and therefore has a more favorable benefit to harm profile than corticosteroids for inflammatory bowel disease.

Colitis, UlcerativeInflammatory Bowel DiseasesCrohn's Disease

University of Pennsylvania9,573 participantsStarted Sep 2014

Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Food and Crohn's Exacerbation Study (FACES)

NCT01926730

The proposed study is a randomized controlled trial of a limited restriction diet compared to a regular diet among patients with Crohn's disease (CD) in remission. At baseline, patients will complete a semi-quantitative food frequency questionnaire assessing usual dietary patterns over the preceding month. Disease activity will be assessed with the abbreviated Crohn's Disease Activity Index (aCDAI)59. Self-reported disease status will be assessed during follow-up using an internet-based questionnaire. Repeat assessment of adherence to the study diets will be assessed with food frequency questionnaires (FFQs) administered after 20 weeks. Follow-up duration will be for 48 weeks. Statistical analysis will compare the time to relapse using Cox regression for patients in the two study arms. In the exploratory aim, we will compare outcomes among patients in the highest tertile for other food items and nutrients to those in the lowest tertile based on self-reported usual dietary patterns at baseline. Thus, the study population will be analyzed both as a randomized controlled trial and as a prospective cohort study.

Crohn's Disease

University of Pennsylvania216 participantsStarted Nov 2013

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329

This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).

Crohn's DiseaseIBDColitis+1 more

Janssen Research & Development, LLC769 participantsStarted Jul 2011

Tucson, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +172 more locations

Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics

Food and Crohn's Exacerbation Study (FACES)

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease Trials in Other Cities

Gene Regulation by Thiazolidinediones

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

T and B Cell Responses in Autoimmune Diseases

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

The Impact of Vitamin D on Disease Activity in Crohn's Disease

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Other Conditions in Philadelphia